Breaking News Instant updates and real-time market news.

NEO

NeoGenomics

$8.32

0.02 (0.24%)

, AET

Aetna

$172.06

-1.85 (-1.06%)

07:03
03/20/18
03/20
07:03
03/20/18
07:03

NeoGenomics names Sharon Virag CFO

NeoGenomics (AET) announced the appointment of George Cardoza as president of the Pharma Services Division and Sharon Virag as CFO. Virag will succeed George Cardoza, who has served as CFO since 2009. Her appointment is effective on March 27, 2018. Sharon Virag was formerly VP, corporate finance and chief accounting officer, at Aetna (AET). George Cardoza's appointment as president of the Pharma Services Division is a newly created position. In 4Q17, the Pharma Services Division reported revenue growth of 69% to $8.7M with a record number of new contracts signed. The Division is adding resources and capacity, including a new Lab in Rolle Switzerland, to meet the growing demand for its services.

NEO

NeoGenomics

$8.32

0.02 (0.24%)

AET

Aetna

$172.06

-1.85 (-1.06%)

  • 16

    Apr

  • 29

    May

  • 30

    May

NEO NeoGenomics
$8.32

0.02 (0.24%)

04/26/17
CANT
04/26/17
NO CHANGE
Target $11
CANT
Overweight
NeoGenomics shares 'oversold' on lowered 2017 guidance, says Cantor
Cantor analyst Bryan Brokmeier reiterates an Overweight rating and a $11 price target on NeoGenomics following mixed Q1 results. The analyst notes that the stock is down after the company revised its 2017 outlook, but he believes shares are oversold. NeoGenomics has now completed its transition period, which had more of a near-term impact on the business than anticipated, he argues, adding that the distractions are behind them and the sales force can now focus on driving new business, including a pipeline of new customers, growing existing accounts, and cross-selling into 100 Clarient IHC-only accounts.
09/11/17
BTIG
09/11/17
DOWNGRADE
BTIG
Neutral
NeoGenomics downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded NeoGenomics to Neutral saying shares are near his $11 price target and sees risk to Q3 revenues given exposure to Texas and Florida, and lack of near-term catalysts.
10/26/17
JANY
10/26/17
NO CHANGE
JANY
Buy
NeoGenomics should be bought on post-earnings weakness, says Janney Capital
Janney Capital analyst Paul Knight believes NeoGenomics can meet and beat estimates now that guidance has been lowered and he recommends buying the shares on any post-earnings weakness. He also noted that the company has already opened its' Switzerland laboratory, ahead of its guidance for a November opening. Knight keeps a Buy rating on NeoGenomics shares.
11/30/17
GABE
11/30/17
NO CHANGE
GABE
Buy
NeoGenomics named a best idea for 2018 at Gabelli
Gabelli analyst Sara Wojda named NeoGenomics a best idea for 2018 citing double-digit volume growth combined with double-digit reduction in cost per test, contined share gains in the core clinical services division, and expectations for stabilization in pricing for FISH tests. Wojda rates NeoGenomics a Buy with a $12 PMV.
AET Aetna
$172.06

-1.85 (-1.06%)

01/31/18
PIPR
01/31/18
NO CHANGE
Target $212
PIPR
Overweight
Piper sees buying opportunity in Aetna after yesterday's pullback
Piper Jaffray analyst Sarah James sees a buying opportunity in Aetna (AET) following yesterday's 3% pullback on the Amazon (AMZN), Berkshire (BRK.A) and JPMorgan (JPM) news. The company yesterday morning posted a solid earnings beat driven by strong cost trend management in the government and commercial businesses, James tells investors in a research note. She raised her price target for Aetna shares to $212 from $207 and keeps an Overweight rating on the name. CVS Health's (CVS) takeout offer now values the shares at $212, up from $207 previously, based on 0.8378 shares of CVS stock plus $145 per share in cash, James points out. The analyst sees a "win-win" setup for the stock based on the deal going through or the company remaining standalone.
01/31/18
RBCM
01/31/18
UPGRADE
Target $98
RBCM
Outperform
Express Scripts upgraded to Outperform at RBC Capital
As reported earlier, RBC Capital analyst George Hill upgraded Express Scripts (ESRX) to Outperform and raised his price target to $98 from $68. Hill cites the "recent sharp pullback on Amazon's (AMZN) healthcare entry" de-risking the stock, while also pointing to the trend of vertical integration as seen in the CVS (CVS)-Aetna (AET) deal. The analyst believes Express Scripts could also become an attractive M&A target as "one of the few remaining assets at scale".
01/31/18
FBCO
01/31/18
NO CHANGE
Target $208
FBCO
Neutral
Aetna price target raised to $208 from $200 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Aetna to $208 from $200, citing on track operationally. However, the analyst is cautious on sustainability of tax benefit. He reiterates a Neutral rating on the shares.
02/01/18
02/01/18
DOWNGRADE
Target $69

Underperform
Express Scripts downgraded to Underperform at Bernstein
As previously reported, Bernstein analyst Lance Wilkes downgraded Express Scripts to Underperform from Market Perform, with a $69 price target, as he believes tax reform is fully price in and his original concerns on the standalone PBM model remain. Further, the analyst sees additional risks from a potential CVS (CVS)/Aetna (AET) merger and Amazon (AMZN) threats.

TODAY'S FREE FLY STORIES

CTRP

Ctrip

$27.31

-0.86 (-3.05%)

06:42
12/18/18
12/18
06:42
12/18/18
06:42
Periodicals
Ctrip CEO says U.S. trade dispute impacted tourism, FT reports »

Ctrip CEO Jane Sun said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

NAV

Navistar

$23.84

-1.93 (-7.49%)

06:37
12/18/18
12/18
06:37
12/18/18
06:37
Earnings
Navistar sees FY19 revenue $10.75B-$11.25B, consensus $10.57B »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

GD

General Dynamics

$163.43

-5.47 (-3.24%)

06:36
12/18/18
12/18
06:36
12/18/18
06:36
Periodicals
General Dynamics warns Canada over scrapping Saudi deal, Reuters reports »

General Dynamics Canadian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

DPW

DPW Holdings

$0.14

-0.0138 (-9.21%)

06:34
12/18/18
12/18
06:34
12/18/18
06:34
Hot Stocks
DPW Holdings authorizes pursuit of IPO for DPW Technology Group »

DPW Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAV

Navistar

$23.84

-1.93 (-7.49%)

06:34
12/18/18
12/18
06:34
12/18/18
06:34
Earnings
Navistar reports Q4 EPS $1.89, consensus $1.71 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CNCE

Concert Pharmaceuticals

$13.69

0.16 (1.18%)

, ACRS

Aclaris Therapeutics

$6.99

-0.31 (-4.25%)

06:33
12/18/18
12/18
06:33
12/18/18
06:33
Recommendations
Concert Pharmaceuticals, Aclaris Therapeutics analyst commentary  »

Concert remains…

CNCE

Concert Pharmaceuticals

$13.69

0.16 (1.18%)

ACRS

Aclaris Therapeutics

$6.99

-0.31 (-4.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPK

Chesapeake Utilities

$87.88

-5.12 (-5.51%)

06:32
12/18/18
12/18
06:32
12/18/18
06:32
Hot Stocks
Chesapeake Utilities subsidiary acquires propane operating assets in PA »

Chesapeake Utilities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMSI

Smith Micro

$1.97

-0.11 (-5.29%)

06:32
12/18/18
12/18
06:32
12/18/18
06:32
Hot Stocks
Smith Micro to acquire ISM Connect Smart Retail suite for $9.8M »

Smith Micro Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$5.94

0.08 (1.37%)

, GSK

GlaxoSmithKline

$37.07

-0.54 (-1.44%)

06:32
12/18/18
12/18
06:32
12/18/18
06:32
Hot Stocks
Epizyme earns $8M milestone payment from GlaxoSmithKline »

Epizyme (EPZM) announced…

EPZM

Epizyme

$5.94

0.08 (1.37%)

GSK

GlaxoSmithKline

$37.07

-0.54 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLS

Flowserve

06:29
12/18/18
12/18
06:29
12/18/18
06:29
Downgrade
Flowserve rating change  »

Flowserve downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$128.13

-2.89 (-2.21%)

06:29
12/18/18
12/18
06:29
12/18/18
06:29
Downgrade
Illinois Tool Works rating change  »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBB

Hubbell

$102.51

-0.405 (-0.39%)

06:28
12/18/18
12/18
06:28
12/18/18
06:28
Downgrade
Hubbell rating change  »

Hubbell downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

06:27
12/18/18
12/18
06:27
12/18/18
06:27
Periodicals
Nissan CEO to meet with Renault boss in Amsterdam, Reuters reports »

Nissan (NSANY) CEO Hiroto…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

MMTOF

Mitsubishi Motors

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

HST

Host Hotels

$17.31

-0.46 (-2.59%)

06:21
12/18/18
12/18
06:21
12/18/18
06:21
Upgrade
Host Hotels rating change  »

Host Hotels upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSA

Public Storage

$199.42

-4.07 (-2.00%)

06:20
12/18/18
12/18
06:20
12/18/18
06:20
Upgrade
Public Storage rating change  »

Public Storage upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUBE

CubeSmart

$30.16

-1.22 (-3.89%)

06:19
12/18/18
12/18
06:19
12/18/18
06:19
Downgrade
CubeSmart rating change  »

CubeSmart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$20.75

-0.62 (-2.90%)

06:19
12/18/18
12/18
06:19
12/18/18
06:19
Downgrade
Invitation Homes rating change  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LSI

Life Storage

$98.10

-3.19 (-3.15%)

06:19
12/18/18
12/18
06:19
12/18/18
06:19
Downgrade
Life Storage rating change  »

Life Storage downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.A

Lionsgate

$15.06

-0.53 (-3.40%)

, LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

06:16
12/18/18
12/18
06:16
12/18/18
06:16
Upgrade
Lionsgate, Use LGF.A, LGF.B, Lionsgate rating change  »

Lionsgate upgraded to Buy…

LGF.A

Lionsgate

$15.06

-0.53 (-3.40%)

LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

LGF.B

Lionsgate

$14.01

-0.48 (-3.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$31.76

-0.63 (-1.95%)

06:14
12/18/18
12/18
06:14
12/18/18
06:14
Hot Stocks
Elanco CEO says 'well positioned to grow top line revenue' »

"Our financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CS

Credit Suisse

$10.94

-0.155 (-1.40%)

06:14
12/18/18
12/18
06:14
12/18/18
06:14
Periodicals
Credit Suisse advises clients to mull shifting assets out of UK, FT reports »

Private bankers at Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

ELAN

Elanco

$31.76

-0.63 (-1.95%)

06:12
12/18/18
12/18
06:12
12/18/18
06:12
Earnings
Elanco sees FY19 adjusted EPS $1.02-$1.12 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

ORCL

Oracle

$45.72

-0.9 (-1.93%)

06:12
12/18/18
12/18
06:12
12/18/18
06:12
Recommendations
Oracle analyst commentary  »

Oracle posted 'solid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDWR

Radware

$22.62

-0.17 (-0.75%)

06:08
12/18/18
12/18
06:08
12/18/18
06:08
Hot Stocks
Radware announces deal with financial information technology provider »

Radware announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATGE

Adtalem Global Education

$50.01

-1.14 (-2.23%)

06:08
12/18/18
12/18
06:08
12/18/18
06:08
Recommendations
Adtalem Global Education analyst commentary  »

Adtalem called a top…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.